An evidence-based approach to psychopharmacology for posttraumatic stress disorder (PTSD) - 2022 update

Bajor, Laura; Balsara, Charmi; Osser, David N.

doi:10.1016/j.psychres.2022.114840

Cited by 19 publications

(6 citation statements)

References 170 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the use of BZD in PTSD has been controversial and frequently ill-advised based on their proposed propensity to interfere with fear extinction in exposure therapy as well as potentiate the development of ongoing stress symptomatology in the aftermath of a traumatic event. 155 , 156 , 157 , 158 …”

Section: Discussionmentioning

confidence: 99%

Prescribing and deprescribing guidance for benzodiazepine and benzodiazepine receptor agonist use in adults with depression, anxiety, and insomnia: an international scoping review

Brandt,

Bressi,

Lê

et al. 2024

eClinicalMedicine

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Prescribing and deprescribing guidance for benzodiazepine and benzodiazepine receptor agonist use in adults with depression, anxiety, and insomnia: an international scoping review

Brandt,

Bressi,

Lê

et al. 2024

eClinicalMedicine

View full text Add to dashboard Cite

“…Timely recognition, appropriate treatment, and ongoing support are crucial in managing PTSD and anxiety, facilitating recovery, and enhancing overall well-being. Standard treatment methods for PTSD and anxiety include, e. g., cognitive-behavioral therapy and antidepressants, modulating serotonin, and norepinephrine reuptake in the neurons [67]. The ECS is important in modulating emotional behaviours and regulating fear, anxiety, and stress-coping processes by modulating synaptic activity at many 'nodes' of the neural circuits involved [68,69].…”

Section: Anxiety and Post-traumatic Stress Disordermentioning

confidence: 99%

Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review

Dammann,

Rohleder,

Leweke

2024

Pharmacopsychiatry

View full text Add to dashboard Cite

The endocannabinoid system shows promise as a novel target for treating psychiatric conditions. Cannabidiol (CBD), a naturally occurring cannabinoid, has been investigated in several psychiatric conditions, with diverse effects and an excellent safety profile compared to standard treatments. Even though the body of evidence from randomised clinical trials is growing, it remains relatively limited in most indications. This review comprises a comprehensive literature search to identify clinical studies on the effects of CBD in psychiatric conditions. The literature search included case studies, case reports, observational studies, and RCTs published in English before July 27, 2023, excluding studies involving nabiximols or cannabis extracts containing CBD and ∆9-tetrahydrocannabinol. Completed studies were considered, and all authors independently assessed relevant publications.Of the 150 articles identified, 54 publications were included, covering the effects of CBD on healthy subjects and various psychiatric conditions, such as schizophrenia, substance use disorders (SUDs), anxiety, post-traumatic stress disorder (PTSD), and autism spectrum disorders. No clinical studies have been published for other potential indications, such as alcohol use disorder, borderline personality disorder, depression, dementia, and attention-deficit/hyperactivity disorder. This critical review highlights that CBD can potentially ameliorate certain psychiatric conditions, including schizophrenia, SUDs, and PTSD. However, more controlled studies and clinical trials, particularly investigating the mid- to long-term use of CBD, are required to conclusively establish its efficacy and safety in treating these conditions. The complex effects of CBD on neural activity patterns, likely by impacting the endocannabinoid system, warrant further research to reveal its therapeutic potential in psychiatry.

show abstract

“…Также одним из эффективных методов коррекции тревоги является применение центральных бета-блокаторов (пропранолол, атенолол, бисопролол) и центральных альфа-адреноблокаторов (празозин, доксазозин). Преимуществом данной группы препаратов является их быстрый анксиолитический эффект, отсутствие выраженной седации, миорелаксации, роста толерантности и нулевой риск формирования зависимости [27][28][29].…”

Section: Doubleblindrandomizedplacebo-controlledstudy Oftheefficacyan...unclassified

Double blind randomized placebo-controlled study of the efficacy and safety of proroxan in the complex therapy of generalized anxiety disorder

Goncharov,

Bereza,

Goncharova

et al. 2024

Medicinskij sovet

View full text Add to dashboard Cite

Introduction. The clinical picture of generalized anxiety disorder is characterized by diffuse anxiety, muscle tension and multiple symptoms of hyperactivity of the sympathetic part of the autonomic nervous system. As an alpha-adrenoblocker, proroxan can reduce the hyperactivity of the autonomic nervous system, thereby reducing the severity of anxiety and its somatic symptoms.Aim. To evaluate the efficacy of proroxan in the correction of autonomic disorders in patients with generalized anxiety disorder compared to placebo.Materials and methods. 100 people participated in the study: 50 – in the study group received the SSRI escitalopram, 50 – in the control group received SSRI + placebo. The diagnosis of generalized anxiety disorder was made on the basis of ICD-10 criteria. Psychometric assessment using the Montgomery-Asberg scale was performed (only at the screening visit). Weekly psychometric evaluation was performed using the Hamilton anxiety scale, the SCL-90-R scale to assess somatic manifestations of anxiety, and general clinical impression scales (CGI-S disease severity and CGI-I general improvement).Results. In the course of the study, statistically significant decrease in the mean value of CGI-S scale was observed in both groups, however, more pronounced in the proroxan group (p > 0.05); in the CGI-I scale, more pronounced improvement was observed in the first week of treatment in the proroxan group (p > 0.05). The HAM-A scale also showed a more significant reduction in anxiety in the proroxan group than in the placebo group (p > 0.05). The SCL-90-R SOM scale showed a decrease in the mean value in both groups, more pronounced in the proroxan group, which confirms the effect of the drug on autonomic symptoms of anxiety (p > 0.05).Conclusions. The obtained results confirm the superiority of combination therapy with escitalopram and proroxan in the treatment of generalized anxiety disorder compared to monotherapy. The advantages of proroxan were the absence of sedative effect and, in general, good tolerability, absence of withdrawal syndrome and control of vegetative manifestations of anxiety.

show abstract

An evidence-based approach to psychopharmacology for posttraumatic stress disorder (PTSD) - 2022 update

Cited by 19 publications

References 170 publications

Prescribing and deprescribing guidance for benzodiazepine and benzodiazepine receptor agonist use in adults with depression, anxiety, and insomnia: an international scoping review

Prescribing and deprescribing guidance for benzodiazepine and benzodiazepine receptor agonist use in adults with depression, anxiety, and insomnia: an international scoping review

Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review

Double blind randomized placebo-controlled study of the efficacy and safety of proroxan in the complex therapy of generalized anxiety disorder

Contact Info

Product

Resources

About